CD4/CD8 Ratio as a Predictor for the Occurrence of Metabolic Syndrome in HIV / AIDS Patients During 6 Months of cART Therapy.
CD4/CD8 ratio
HIV/AIDS
cART
metabolic syndrome
Journal
Journal of medical biochemistry
ISSN: 1452-8258
Titre abrégé: J Med Biochem
Pays: Serbia
ID NLM: 101315490
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
30
10
2018
accepted:
17
12
2018
entrez:
10
9
2019
pubmed:
10
9
2019
medline:
10
9
2019
Statut:
epublish
Résumé
HIV infection is characterized by progressive depletion of CD4 80 HIV/AIDS subjects were included in a retrospective case-control study. Flow cytometry was used to determine the percentage of CD4 After six months of cART therapy 19 (23.8%) subjects had all the elements necessary for making the diagnosis of MetS. Using multivariate analysis CD4/CD8 ratio was statistically significant (p < 0.05) and had the largest effect on development of MetS (Wald = 9.01; OR = 0.45), followed by cART (Wald = 7.87; OR = 0.10) and triglycerides (Wald = 5.27; OR = 1.7). On the other hand, body weight and waist circumference showed no statistically significant effect on the development of MetS after six months of cART, p > 0.05. CD4/CD8 ratio proved to be a significant marker for prediction of metabolic syndrome in HIV/AIDS patients. HIV-infekcija se karakteriše progresivnim gubitkom CD4 U retrospektivnoj studiji slučaj/kontrola je bilo uključeno 80 HIV/AIDS ispitanika. Za određivanje udela (procenta) CD4 Nakon 6 meseci cART terapije 19 (23,8%) ispitanika je ispunjavalo sve kriterijume za postavljanje dijagnoze MS. Multivarijantnom analizom statistički značajan (p < 0,05) i najveći uticajan na razvoj MS je imao količnik CD4/CD8 (Wald = 9,01; OR = 0,45), potom cART (Wald = 7,87; OR = 0,10), i na kraju trigliceridi (Wald = 5,27; OR = 1,7). S druge strane, telesna težina i obim struka nisu pokazali statistički značajan uticaj na razvoj MS nakon {est meseci cART, p > 0,05. Količnik CD4/CD8 se pokazao se kao značajan marker u predikciji metaboličkog sindroma kod HIV/AIDS pacijenata.
Sections du résumé
BACKGROUND
BACKGROUND
HIV infection is characterized by progressive depletion of CD4
METHODS
METHODS
80 HIV/AIDS subjects were included in a retrospective case-control study. Flow cytometry was used to determine the percentage of CD4
RESULTS
RESULTS
After six months of cART therapy 19 (23.8%) subjects had all the elements necessary for making the diagnosis of MetS. Using multivariate analysis CD4/CD8 ratio was statistically significant (p < 0.05) and had the largest effect on development of MetS (Wald = 9.01; OR = 0.45), followed by cART (Wald = 7.87; OR = 0.10) and triglycerides (Wald = 5.27; OR = 1.7). On the other hand, body weight and waist circumference showed no statistically significant effect on the development of MetS after six months of cART, p > 0.05.
CONCLUSIONS
CONCLUSIONS
CD4/CD8 ratio proved to be a significant marker for prediction of metabolic syndrome in HIV/AIDS patients.
UVOD
UNASSIGNED
HIV-infekcija se karakteriše progresivnim gubitkom CD4
METODE
METHODS
U retrospektivnoj studiji slučaj/kontrola je bilo uključeno 80 HIV/AIDS ispitanika. Za određivanje udela (procenta) CD4
REZULTATI
UNASSIGNED
Nakon 6 meseci cART terapije 19 (23,8%) ispitanika je ispunjavalo sve kriterijume za postavljanje dijagnoze MS. Multivarijantnom analizom statistički značajan (p < 0,05) i najveći uticajan na razvoj MS je imao količnik CD4/CD8 (Wald = 9,01; OR = 0,45), potom cART (Wald = 7,87; OR = 0,10), i na kraju trigliceridi (Wald = 5,27; OR = 1,7). S druge strane, telesna težina i obim struka nisu pokazali statistički značajan uticaj na razvoj MS nakon {est meseci cART, p > 0,05.
ZAKLJUČAK
UNASSIGNED
Količnik CD4/CD8 se pokazao se kao značajan marker u predikciji metaboličkog sindroma kod HIV/AIDS pacijenata.
Autres résumés
Type: Publisher
(srp)
HIV-infekcija se karakteriše progresivnim gubitkom CD4
Identifiants
pubmed: 31496914
doi: 10.2478/jomb-2018-0049
pii: jomb-2018-0049
pmc: PMC6708296
doi:
Types de publication
Journal Article
Langues
eng
Pagination
489-495Déclaration de conflit d'intérêts
Conflict of interest Conflict of interest statement: The authors stated that they have no conflicts of interest regarding the publication of this article.
Références
J Acquir Immune Defic Syndr. 2000 Nov 1;25(3):203-11
pubmed: 11115950
Clin Infect Dis. 2007 Mar 1;44(5):726-34
pubmed: 17278068
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):478-85
pubmed: 20717021
Curr Opin HIV AIDS. 2012 Mar;7(2):111-6
pubmed: 22227586
Clin Dev Immunol. 2012;2012:925135
pubmed: 22474485
PLoS Pathog. 2014 May 15;10(5):e1004078
pubmed: 24831517
Curr Opin HIV AIDS. 2015 Jan;10(1):35-42
pubmed: 25415420
AIDS. 2015 Mar 13;29(5):595-607
pubmed: 25715104
Lancet HIV. 2015 Mar;2(3):e98-106
pubmed: 26424550
Medicine (Baltimore). 2016 Mar;95(11):e3108
pubmed: 26986155
PLoS One. 2016 Mar 23;11(3):e0150970
pubmed: 27008536
Clin Infect Dis. 2016 Aug 1;63(3):425-6
pubmed: 27143670
Medicine (Baltimore). 2016 Oct;95(42):e5094
pubmed: 27759638
HIV Clin Trials. 2017 May;18(3):110-117
pubmed: 28420298
AIDS Res Ther. 2018 Sep 27;15(1):13
pubmed: 30261902
J Med Biochem. 2017 Oct 28;36(4):366-374
pubmed: 30581334
J Med Biochem. 2018 Jul 01;37(3):279-288
pubmed: 30584397